Linda Joosten

149 CLINICAL CONSEQUENCES OF OFF-LABEL REDUCED DOSING OF NOACS IN AF 19. Boehringer Ingelheim Pharma GmbH & Co KG. Summary of product characteristics of dabigatran. [Internet]. [cited 2021 Oct 1]. Available from: https://www.ema.europa.eu/ en/documents/product-information/pradaxa-epar-product-information_en.pdf 20. Bayer Pharma AG and Bayer HealthCare Manufacturing S.r.l. Summary of product characteristics of rivaroxaban. [Internet]. [cited 2021 Oct 1]. Available from: https://www. ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_ en.pdf 21. Bristol-Myers Squibb S.r.l. and Phizer Manufacturing Deutschland GmbH. Summary of product characteristics of apixaban. [Internet]. [cited 2021 Oct 1]. Available from: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-productinformation_en.pdf 22. Daiichi Sankyo Europa GmbH. Summary of product characteristics of edoxaban. [Internet]. [cited 2021 Oct 1]. Available from: https://www.ema.europa.eu/en/documents/productinformation/lixiana-epar-product-information_en.pdf 23. Food and Drugs Adm. Highlights of prescribing information of dabigatran. [Internet]. 2020 [cited 2021 Oct 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2020/022512s039lbl.pdf 24. Food and Drugs Adm. Highlights of prescribing information of rivaroxaban. [Internet]. 2021 [cited 2021 Oct 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2021/022406s036,202439s036lbl.pdf 25. Food and Drugs Adm. Highlights of prescribing information of apixaban. [Internet]. 2021 [cited 2021 Oct 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2021/202155s032lbl.pdf 26. Food and Drugs Adm. Highlights of prescribing information of edoxaban. [Internet]. 2020 [cited 2021 Oct 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2020/206316s016lbl.pdf 27. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. 28. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;1–65. 29. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2013. 30. Inthout J, Ioannidis J, Borm G. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25. 31. R. Core Team. R: a language and environment for statistical computing. [Internet]. R Foundation for Statistical Computing Vienna Austria. 2015. 32. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48. 33. Arbel R, Sergienko R, Hammerman A, Greenberg-Dotan S, Batat E, Avnery O, et al. Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation. Am J Med. 2019;132(7):847-55.e3. 34. Atarashi H, Uchiyama S, Inoue H, Kitazono T, Yamashita T, Shimizu W, et al. Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: Sub-analysis of the EXPAND study. Heart Vessels. 2021;36(9):1410–20. 8

RkJQdWJsaXNoZXIy MTk4NDMw